Cantargia Logo


ISIN: SE0006371126 | Ticker: CANTA | LEI: 549300GKWRT7RXI4VS85
Sector: Health CareSub-Industry: Biotechnology
Country: Sweden

About Cantargia

Company Description

Cantargia is a Swedish biotechnology company that specializes in the development of pharmaceuticals for various types of cancer and inflammatory/autoimmune diseases. Our development programme includes the candidate drugs nadunolimab (CAN04), currently in phase IIa clinical studies, and CAN10, currently in preclinical phase, as well as our discovery project CANxx. The company is listed on OMX Stockholm’s Main List (Mid Cap).

Cantargia AB was founded in 2009-2010 with the aim of refining a discovery by Professor Thoas Fioretos and Doctor Marcus Järås of Lund University. Their research showed that leukemic stem cells express a protein on their surface – IL1RAP – that is not expressed to as great a degree on normal stem cells. Further research demonstrated that this protein is also found on cancer cells from a large number of solid tumor types.

Year founded



Scheelevägen 27, 22363 Lund – Sweden

Filings & Publications

Sign up and we will give you access!

Insider Trades

Date Trading entity / Person Association Trade type Volume
19.01.23 Nedjad Losic Other Buy SEK 29,110.74
17.01.23 Göran Forsberg Other Buy SEK 140,250.00
17.01.23 Bengt Jöndell Other Buy SEK 54,665.00
28.07.22 Göran Forsberg Other Other SEK 344,118.75
28.07.22 Thoas Fioretos Other Other SEK 294,000.00
28.07.22 Bengt Jöndell Other Other SEK 284,996.25
28.07.22 Gunnar Magnus Severus Modée Persson Other Other SEK 168,660.00
28.07.22 Magnus Nilsson Other Buy SEK 108,961.82
28.07.22 Liselotte Larsson Other Other SEK 78,997.50
28.07.22 David Liberg Other Other SEK 27,990.00

Capital markets information






Health Care

Industry Group

Pharmaceuticals, Biotechnology & Life Sciences





Listed Stock Exchange

Nasdaq Stockholm

Contact Investor Relations department

Stay up to date

Keep yourself informed with the most recent updates on FinancialReports, IPOs, product advancements, and other significant news.